Cybin Reports Massive $148M Net Loss and High Cash Burn for FY26 Amidst Clinical Progress
HELP sits 83% above its 52-week low of $3.76.
Summary
Cybin Inc. reported a massive net loss of $148.0 million and cash burn of $131.7 million for fiscal year 2026, significantly worsening its financial position despite recently closing a $50 million underwritten offering.
Key Events · Financing and Capital Events · HELP
-
Massive Net Loss Reported
The company reported a net loss of $148.0 million for fiscal year 2026, a significant increase from $81.6 million in the prior year.
-
High Cash Burn Continues
Cash-based operating expenses rose to $131.7 million for the year, up from $71.8 million, indicating an accelerating cash burn rate.
-
Recent $50 Million Offering Closed
The company confirmed the closing of a $50 million underwritten offering on June 25, 2026, which bolsters its balance sheet for ongoing clinical trials.
-
Clinical Trial Progress
The HLP003 Phase 3 APPROACH study for MDD has surpassed 88% enrollment, with topline data expected in Q4 2026. Positive Phase 2 data for HLP004 in GAD was also reported.
Analysis · HELP · Life Sciences
Cybin Inc.'s financial results for fiscal year 2026 reveal a substantial increase in net losses and cash burn, which are unsustainable given its current market valuation. While the recently closed $50 million offering provides a temporary cash infusion, the high burn rate indicates a critical need for ongoing capital, overshadowing positive clinical updates for its HLP003 and HLP004 programs. This raises significant concerns about the company's long-term financial viability.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 46.5% of the 301 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $6.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $9.83. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.